November 25, 2024
June 11, 2024
A Spring Group Meeting recap; a milestone for TMIST; a new myeloMATCH treatment trial
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy